- Tharimmune (THAR, Financial) set to present clinical data on TH104 at two major medical conferences in May 2025.
- The presentations will focus on TH104's pharmacokinetics and its metabolism for treating pruritus in PBC.
- These presentations highlight TH104's potential in addressing unmet needs in immunological and inflammatory disorders.
Tharimmune, Inc. (NASDAQ: THAR) has announced the acceptance of abstracts featuring clinical data on its lead drug candidate, TH104, for presentation at the upcoming Digestive Disease Week (DDW) in San Diego and the European Association for the Study of the Liver (EASL) International Liver Congress in Amsterdam. These important medical conferences will take place in May 2025.
During the Digestive Disease Week, Tharimmune will present data on the pharmacokinetics of TH104 in healthy subjects. This poster session will be held on May 5, 2025, from 12:30 PM to 1:30 PM PDT at the San Diego Convention Center. This presentation is part of a larger discussion on cholelithiasis and biliary tract disorders, providing insights into the clinical advancements of TH104.
The EASL International Liver Congress will feature a presentation on the metabolism of TH104, focusing on its application for treating pruritus associated with Primary Biliary Cholangitis (PBC). This session is scheduled for May 7, 2025, at the RAI Convention Centre in Amsterdam. This marks a significant step in highlighting the potential of TH104 in managing rare liver diseases and addressing significant unmet medical needs.
Tharimmune continues to advance its drug portfolio through innovative research, with TH104 being developed for unmet immunological and inflammatory conditions. The company's presentations at these conferences underscore its commitment to pioneering therapeutic solutions with the potential to improve patient outcomes.
